Inventaire - your friends and communities are your best library - Inventaire

Targeting the mTOR signaling pathway in neuroendocrine tumors

published in: Current Treatment Options in Oncology

date of publication: 2014-09-01

language: English

main subject: neuroendocrine tumor, enzyme, mechanism of action, signal transduction, antineoplastic, Serine/threonine-protein kinase TOR

Cites articles 55

Date

Title

Authors

2013-03-01

Everolimus in advanced pancreatic neuroendocrine tumors: the clinical experience
2013-06-03

A prospective, phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumor

Jeffrey A Meyerhardt
2013-04-01

Regulation of mTORC1 and its impact on gene expression at a glance

David M. Sabatini
2013-08-26

Prognostic significance of MTOR pathway component expression in neuroendocrine tumors

Zhi Rong Qian, Monica Ter-Minassian, Shuji Ogino, Charles S. Fuchs, Xihong Lin, David C. Christiani, Teppei Morikawa
2013-02-01

The genetics of neuroendocrine tumors
2012-04-13

mTOR signaling in growth control and disease

David M. Sabatini
2012-12-21

Everolimus plus octreotide long-acting repeatable in patients with colorectal neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-2 study

Thomas O'Dorisio
2012-09-11

Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study
2011-12-14

Clinical review: Current scientific rationale for the use of somatostatin analogs and mTOR inhibitors in neuroendocrine tumor therapy
2011-04-11

Everolimus induces rapid plasma glucose normalization in insulinoma patients by effects on tumor as well as normal tissues
2011-02-01

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors

Eric Van Cutsem, Bertram Wiedenmann, Catherine Lombard-Bohas, Yung-Jue Bang
2011-01-24

Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting

Eric Van Cutsem
2011-01-06

AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity

Josep Baselga, Violeta Serra
2011-03-01

VEGFR-2 expression in carcinoid cancer cells and its role in tumor growth and metastasis

Courtney M. Townsend, B Mark Evers
2011-01-13

mTOR expression and activity patterns in gastroenteropancreatic neuroendocrine tumours.

Carsten Denkert, Christoph Röcken, Manfred Dietel, Wilko Weichert, Hironobu Sasano
2011-05-01

Advances in pancreatic neuroendocrine tumor treatment.

Massimo Terzolo
2011-03-04

DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors

Bert Vogelstein, Luis Alberto Diaz Jr, Victor Velculescu, Kenneth W Kinzler, Ralph H. Hruban, Christopher L Wolfgang, Anirban Maitra, Richard D Schulick, David S Klimstra, Barish H Edil, Nickolas Papadopoulos, Michael A Choti, Yuchen Jiao, Chanjuan Shi, Laura A Tang
2010-12-15

mTOR: from growth signal integration to cancer, diabetes and ageing

Alejo Efeyan, David M. Sabatini
2010-08

The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems

David S Klimstra
2010-09-07

First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas

Domenico Coppola
2009-05-01

Targeting the mTOR signaling network for cancer therapy

Funda Meric-Bernstam, Ana Maria Gonzalez-Angulo
2009-11-23

Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial

Eric Van Cutsem, Bertram Wiedenmann, Catherine Lombard-Bohas, Thomas O'Dorisio
2009-07-07

An analysis of trends and growth factor receptor expression of GI carcinoid tumors

B Mark Evers
2009-01-01

Molecular genetics of gastroenteropancreatic neuroendocrine tumors
2009-01-01

O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors

Jeffrey A Meyerhardt, Charles S. Fuchs
2009-08-24

Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group

Carmen Schade-Brittinger, Thomas Gress
2009-05

Molecular mechanisms of mTOR-mediated translational control
2009-01-01

Glycemic control in patients with insulinoma treated with everolimus
2009-11-16

Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway

Stefano Barbi, Marco Della Peruta, Edoardo Missiaglia, Lorenzo Piemonti, Aldo Scarpa, Massimo Falconi, Carlo Maria Croce, Gabriele Capurso
2008-09-01

Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study

Funda Meric-Bernstam
2008-03-01

Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors.

Funda Meric-Bernstam, Mark F Munsell
2008-03-01

Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b

Jaffer Ajani

Article - wd:Q26852089

Welcome to Inventaire

the library of your friends and communities

you are offline